Literature DB >> 14987741

Persistence of recipient lymphocytes in NOD mice after irradiation and bone marrow transplantation.

Raymond J Steptoe1, Sanda Stankovic, Sash Lopaticki, Lynelle K Jones, Leonard C Harrison, Grant Morahan.   

Abstract

The non-obese diabetic (NOD) mouse is a unique and invaluable model of autoimmune disease, in particular type 1 diabetes. Bone marrow transplantation as a therapy for type 1 diabetes has been explored in NOD mice. NOD mice require higher doses of conditioning irradiation for successful allogeneic bone marrow transplantation, suggesting that NOD hematopoietic cells are radioresistant compared to those of other mouse strains. However, studies of hematopoietic reconstitution in NOD mice are hampered by the lack of mice bearing a suitable cell-surface marker that would allow transferred cells or their progeny to be distinguished. In order to monitor hematopoietic reconstitution in NOD mice we generated congenic NOD mice that carry the alternative allelic form of the pan-leukocyte alloantigen CD45. Following irradiation and congenic bone marrow transplantation, we found that the myeloid lineage was rapidly reconstituted by cells of donor origin but substantial numbers of recipient T lymphocytes persisted even after supra-lethal irradiation. This indicates that radiation resistance in the NOD hematopoietic compartment is a property primarily of mature T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14987741     DOI: 10.1016/j.jaut.2003.12.003

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  7 in total

1.  Tet2 Controls the Responses of β cells to Inflammation in Autoimmune Diabetes.

Authors:  Jinxiu Rui; Songyan Deng; Ana Luisa Perdigoto; Gerald Ponath; Romy Kursawe; Nathan Lawlor; Tomokazu Sumida; Maya Levine-Ritterman; Michael L Stitzel; David Pitt; Jun Lu; Kevan C Herold
Journal:  Nat Commun       Date:  2021-08-20       Impact factor: 14.919

2.  APC-targeted proinsulin expression inactivates insulin-specific memory CD8+ T cells in NOD mice.

Authors:  Peta Ls Reeves; Rajeev Rudraraju; Xiao Liu; F Susan Wong; Emma E Hamilton-Williams; Raymond J Steptoe
Journal:  Immunol Cell Biol       Date:  2017-06-14       Impact factor: 5.126

3.  Interleukin-1β produced in response to islet autoantigen presentation differentiates T-helper 17 cells at the expense of regulatory T-cells: Implications for the timing of tolerizing immunotherapy.

Authors:  Sebastien Bertin-Maghit; Dimeng Pang; Brendan O'Sullivan; Shannon Best; Emily Duggan; Sanjoy Paul; Helen Thomas; Thomas W H Kay; Leonard C Harrison; Raymond Steptoe; Ranjeny Thomas
Journal:  Diabetes       Date:  2010-10-27       Impact factor: 9.461

4.  Complete diabetes protection despite delayed thymic tolerance in NOD8.3 TCR transgenic mice due to antigen-induced extrathymic deletion of T cells.

Authors:  Balasubramanian Krishnamurthy; Jonathan Chee; Gaurang Jhala; Stacey Fynch; Kate L Graham; Pere Santamaria; Grant Morahan; Janette Allison; David Izon; Helen E Thomas; Thomas W H Kay
Journal:  Diabetes       Date:  2011-12-21       Impact factor: 9.461

5.  Immunogenic, but not steady-state, antigen presentation permits regulatory T-cells to control CD8+ T-cell effector differentiation by IL-2 modulation.

Authors:  Alice McNally; Michael McNally; Ryan Galea; Ranjeny Thomas; Raymond J Steptoe
Journal:  PLoS One       Date:  2014-01-13       Impact factor: 3.240

6.  Short-course rapamycin treatment enables engraftment of immunogenic gene-engineered bone marrow under low-dose irradiation to permit long-term immunological tolerance.

Authors:  Kunal H Bhatt; Rajeev Rudraraju; Jeremy F Brooks; Ji-Won Jung; Ryan Galea; James W Wells; Raymond J Steptoe
Journal:  Stem Cell Res Ther       Date:  2017-03-09       Impact factor: 6.832

7.  Expression profiling pre-diabetic mice to uncover drugs with clinical application to type 1 diabetes.

Authors:  Dimeng Pang; Katharine M Irvine; Ahmed M Mehdi; Helen E Thomas; Mark Harris; Emma E Hamilton-Williams; Ranjeny Thomas
Journal:  Clin Transl Immunology       Date:  2015-08-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.